Search

Displaying results 331 - 340 of 2454 in total
  1. Drug

    Pibrentasvir

    go.drugbank.com/drugs/DB13878
    ApprovedInvestigational

    Pibrentasvir is a direct acting antiviral agent and Hepatitis C virus (HCV) NS5A inhibitor that targets the the viral RNA replication and viron assembly. In combination with DB13879, pibrentastiv is a useful therapy for patients who expe...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    PF-04634817

    go.drugbank.com/drugs/DB14955
    Investigational

    PF-04634817 is under investigation in clinical trial NCT01140672 (A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects).

  3. Drug

    PF-07038124

    go.drugbank.com/drugs/DB19143
    Investigational

    PF-07038124 is under investigation in clinical trial NCT05298033 (Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo).

  4. Drug

    ATG-101

    go.drugbank.com/drugs/DB17162
    Investigational

    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors

    Synonyms: PD-L1/4-1BB bispecific antibody
  5. Drug

    Riociguat

    go.drugbank.com/drugs/DB08931
    ApprovedInvestigational

    with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  6. Drug

    PF-04418948

    go.drugbank.com/drugs/DB12024
    Investigational

    Pf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers).

  7. Drug

    PF-04457845

    go.drugbank.com/drugs/DB12012
    Investigational

    PF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.

  8. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer. However...

  9. Drug

    Doconexent

    go.drugbank.com/drugs/DB03756
    ApprovedInvestigational

    A mixture of fish oil and primrose oil, doconexent is used as a high-docosahexaenoic acid (DHA) supplement. DHA is a 22 carbon chain with 6 cis double bonds with anti-inflammatory effects. It can be biosythesized from alpha-linolenic aci...

    Mixtures: P-NATAL®, Virt-Pn DHACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Inhibitors
  10. Drug

    PF-05089771

    go.drugbank.com/drugs/DB14856
    Investigational

    PF-05089771 is under investigation in clinical trial NCT01529671 (A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee).